Trial intelligence / Profile preview

Drug-drug interaction study of OP-2024 with opicapone in healthy male volunteers

jRCT2031250157Phase 1Completed

Sponsor
Ohara Pharmaceutical Co., Ltd.
Start
Sep 2025
Modality
Small Molecules
Countries
1
01

Overview

Phase 1 trial of XI Ning in Parkinson's disease (PD) (2 arms), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetics. Started Sep 2025; status: completed.

02

Drugs

XI Ning
03

Conditions

Parkinson's disease (PD)

Beyond the preview

Go deeper on jRCT2031250157.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2031250157.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call